


## Grazoprevir hydrate

## Chemical Properties

CAS No. :	1350462-55-3
Formula:	C <sub>38</sub> H <sub>52</sub> N <sub>6</sub> O <sub>10</sub> S
Molecular Weight:	784.92
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Grazoprevir, a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets, has good activity against a range of hepatitis C virus genotype variants, including some that are resistant to most currently used antiviral medications.
Targets(IC50)	Others,HCV Protease,SARS-CoV

## Solubility Information

Solubility	DMSO: Soluble, H <sub>2</sub> O: Insoluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.274 mL	6.3701 mL	12.7402 mL
5 mM	0.2548 mL	1.274 mL	2.548 mL
10 mM	0.1274 mL	0.637 mL	1.274 mL
50 mM	0.0255 mL	0.1274 mL	0.2548 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterson JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3. *Clin Ther*. 2018 Apr 24. pii: S0149-2918(18)30094-8. doi: 10.1016/j.clinthera.2018.03.002. [Epub ahead of print] PubMed PMID: 29703432.
- Zamor PJ, Vierling J, Ghalib R, Luketic V, Ravendhran N, Balart L, Robertson M, Hwang P, Hanna GJ, Nguyen BY, Barr E, Talwani R, Pearlman B. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. *Am J Gastroenterol*. 2018 Apr 26. doi: 10.1038/s41395-018-0053-4. [Epub ahead of print] PubMed PMID: 29695828.
- Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, Younossi Z, Afdhal N. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. *Aliment Pharmacol Ther*. 2018 Apr 17. doi: 10.1111/apt.14635. [Epub ahead of print] PubMed PMID: 29665097.
- Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N. Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. *Oncotarget*. 2018 Mar 23;9(22):16263-16270. doi: 10.18632/oncotarget.24620. eCollection 2018 Mar 23. PubMed PMID: 29662642; PubMed Central PMCID: PMC5882333.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481